One of the most successful cases is the application of TKIs in non-small cell lung cancer with EGFR mutation557 and chronic myeloid leukemia558, which is partially mediated by the blockage of the signal transduction stimulated by DDRs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.